Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Neuro Oncol ; 16(11): 1554-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24847085

ABSTRACT

BACKGROUND: The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective. METHODS: Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for this multicenter phase II trial. The anti-epidermal growth factor receptor (EGFR) antibody, nimotuzumab (150 mg/m(2)), was administered intravenously once weekly from weeks 1 to 7 and once every 2 weeks from weeks 8 to 18. Response evaluation was based on clinical and MRI assessments. Patients with partial response (PR) or stable disease (SD) were allowed to continue nimotuzumab. RESULTS: Forty-four patients received at least one dose of nimotuzumab (male/female, 20/24; median age, 6.0 years; range, 3.0-17.0 years). All had received prior radiotherapy. Treatment was well tolerated. Eighteen children experienced serious adverse events (SAEs). The majority of SAEs were associated with disease progression. Nineteen patients completed 8 weeks (W8) of treatment: There were 2 PRs, 6 SDs, and 11 progressions. Five patients completed 18 weeks (W18) of treatment: 1 of 2 patients with PR at W8 remained in PR at W18, and 3 of 6 children with SD at W8 maintained SD at W18. Time to progression following initiation of nimotuzumab for the 4 patients with SD or better at W18 was 119, 157, 182 and 335 days, respectively. Median survival time was 3.2 months. Two patients lived 663 and 481 days from the start of nimotuzumab. CONCLUSIONS: Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Brain Stem Neoplasms/drug therapy , Glioma/drug therapy , Neoplasm Recurrence, Local/drug therapy , Adolescent , Brain Stem Neoplasms/mortality , Brain Stem Neoplasms/pathology , Child , Child, Preschool , Cohort Studies , Disease Progression , Female , Follow-Up Studies , Glioma/mortality , Glioma/pathology , Humans , Male , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Safety , Survival Rate
2.
Pediatr Blood Cancer ; 61(1): 128-33, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23956145

ABSTRACT

BACKGROUND: The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms. This phase I study aimed to explore the safety and toxicity of this combination in pediatric patients with advanced solid tumors. PROCEDURE: Patients ≤21 years of age with recurrent/refractory solid tumors (including CNS) were eligible. Sirolimus was administered daily by mouth or nasogastric (NG) tube, with doses adjusted to achieve a target trough concentration of 10-15 ng/ml, with weekly intravenous vinblastine (dose escalated 4-6 mg/m(2)/dose according to 3 + 3 phase I design). RESULTS: Fourteen patients were enrolled (median age 8.7 years; range 2.3-19) of whom 12 were evaluable for toxicity and 11 for response. One patient experienced a dose-limiting toxicity (grade 3 mucositis) at the highest vinblastine dose level. Myelosuppression was the most common toxicity. Dose-adjusted sirolimus trough concentrations were significantly lower in patients receiving drug via NG tube (1.50 ± 0.75 ng/ml/mg vs. 2.25 ± 1.07 ng/ml/mg for oral administration). Correlative biomarker analysis demonstrated a significant reduction in serum concentration of soluble vascular endothelial growth factor receptor (sVEGFR2) at 28 days compared to baseline consistent with inhibition of angiogenesis. One patient had a partial response and three had stable disease for more than 3 months. CONCLUSIONS: The combination of mTOR inhibitor and vinblastine given over an extended continuous schedule is safe, associated with a reduction in circulating angiogenic factor (CAF) VEGFR2 and resulted in clinical responses. Future studies using the intravenously administered mTOR inhibitor temsirolimus are planned.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms/drug therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm/drug effects , Female , Humans , Male , Maximum Tolerated Dose , Neoplasm Recurrence, Local/drug therapy , Receptors, Vascular Endothelial Growth Factor/blood , Sirolimus/administration & dosage , Sirolimus/adverse effects , Sirolimus/pharmacokinetics , Vascular Endothelial Growth Factor A/blood , Vinblastine/administration & dosage , Vinblastine/adverse effects , Vinblastine/pharmacokinetics , Young Adult
3.
CMAJ ; 183(17): E1252-8, 2011 Nov 22.
Article in English | MEDLINE | ID: mdl-22007121

ABSTRACT

BACKGROUND: The choice between palliative chemotherapy (defined as the use of cytotoxic medications delivered intravenously for the purpose of our study) and supportive care alone is one of the most difficult decisions in pediatric oncology, yet little is known about the preferences of parents and health care professionals. We compared the strength of these preferences by considering children's quality of life and survival time as key attributes. In addition, we identified factors associated with the reported preferences. METHODS: We included parents of children whose cancer had no reasonable chance of being cured and health care professionals in pediatric oncology as participants in our study. We administered separate interviews to parents and to health care professionals. Visual analogue scales were shown to respondents to illustrate the anticipated level of the child's quality of life, the expected duration of survival and the probability of cure (shown only to health care professionals). Respondents were then asked which treatment option they would favour given these baseline attributes. In addition, respondents reported what factors might affect such a decision and ranked all factors identified in order of importance. The primary measure was the desirability score for supportive care alone relative to palliative chemotherapy, as obtained using the threshold technique. RESULTS: A total of 77 parents and 128 health care professionals participated in our study. Important factors influencing the decision between therapeutic options were child quality-of-life and survival time among both parents and health care professionals. Hope was particularly important to parents. Parents significantly favoured chemotherapy (42/77, 54.5%) compared with health care professionals (20/128, 15.6%; p < 0.0001). The opinions of the physician and child significantly influenced the parents' desire for supportive care; for health care professionals, the opinions of parents and children were significant factors influencing this decision. INTERPRETATION: Compared with health care professionals, parents more strongly favour aggressive treatment in the palliative phase and rank hope as a more important factor for making decisions about treatment. Understanding the differences between parents and health care professionals in the relative desirability of supportive care alone may aid in communication and improve end-of-life care for children with cancer.


Subject(s)
Antineoplastic Agents/therapeutic use , Attitude of Health Personnel , Neoplasms/therapy , Palliative Care , Parents/psychology , Pediatrics , Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Neoplasms/mortality , Neoplasms/pathology , Patient Preference , Quality of Life , Survival Rate
4.
Eur J Cancer ; 46(18): 3271-9, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20656474

ABSTRACT

PURPOSE: Survival rates for paediatric diffuse intrinsic brainstem glioma (DIBSG) are dismal. Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ. This study aimed to evaluate the safety and efficacy of this regimen in paediatric DIBSG patients. METHODS: Children aged 18 years or younger with newly diagnosed DIBSG were treated with standard radiotherapy and concomitant metronomic TMZ at 85 mg/m(2)/day for 6 weeks, followed by metronomic TMZ monotherapy at the same dose. Treatment was continued until tumour progression or unacceptable toxicity occurred. Primary endpoints included overall survival and toxicities. For patients who consented, plasma and urine samples were collected at diagnosis, post-induction and prior to each course of maintenance therapy for the quantification of angiogenesis markers. RESULTS: Fifteen eligible patients were enrolled, with a median age of 6.4 years. The most common toxicities were myelosuppression, most notably prolonged lymphopaenia and thrombocytopaenia. The only dose-limiting toxicity was thrombocytopaenia. Intratumoural haemorrhage was confirmed in one patient. Median time to progression was 5.13 months (95% CI = 6.4, 10.8) and median overall survival (OS) was 9.8 months (95% CI = 6.4, 10.8). Six-months OS was 80% ± 10.3%, with a 1-year OS of 20% ± 10.3%. Serum levels of both VEGF and endoglin tended to decrease during the first two cycles of therapy. CONCLUSION: Chemoradiotherapy with metronomic dosing of TMZ showed similar toxicity to previous TMZ regimens, and does not appear to improve survival in paediatric DIBSG.


Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Brain Stem Neoplasms/drug therapy , Brain Stem Neoplasms/radiotherapy , Dacarbazine/analogs & derivatives , Glioma/drug therapy , Glioma/radiotherapy , Adolescent , Antineoplastic Agents, Alkylating/adverse effects , Canada , Child , Child, Preschool , Combined Modality Therapy/methods , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Female , Humans , Infant , Male , Maximum Tolerated Dose , Pilot Projects , Temozolomide , Thrombocytopenia/etiology , Treatment Outcome
5.
Eur J Cancer ; 45(13): 2352-9, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19505817

ABSTRACT

PURPOSE: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA. METHODS: Nineteen patients aged 2-18 years, with recurrent or refractory CNS tumours expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry) were eligible. Participants received imatinib orally at a dose of 440 mg/m(2)/day and toxicities and tumour responses were monitored. Serial blood and cerebrospinal fluid samples for pharmacokinetics were obtained in a subset of consenting patients. Frozen tumour samples were analysed retrospectively for KIT and PDGFRA gene amplification in a subset of patients for whom samples were available. RESULTS: Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated serum transaminases and vomiting. No intratumoural haemorrhages were observed. Although there were no objective responses to imatinib, four patients had long-term stable disease (SD) (38-104 weeks). Our results suggest a possible relationship between KIT expression and maintenance of SD with imatinib treatment; KIT immunopositivity was seen in only 58% (11/19) of study participants overall, but in 100% of patients with SD at 38 weeks. All patient tumours showed PDGFRA expression. Pharmacokinetic data showed a high interpatient variability, but corresponded with previously reported values. CONCLUSIONS: Imatinib at 440 mg/m(2)/day is relatively safe in children with recurrent CNS tumours, but induced no objective responses. Demonstration of SD in previously progressing patients (KIT-expressing) suggests cytostatic activity of imatinib.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Central Nervous System Neoplasms/metabolism , Piperazines/pharmacokinetics , Protein Kinase Inhibitors/pharmacokinetics , Proto-Oncogene Proteins c-kit/metabolism , Pyrimidines/pharmacokinetics , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Adolescent , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Benzamides , Canada , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/genetics , Child , Child, Preschool , Drug Resistance, Neoplasm/genetics , Female , Humans , Imatinib Mesylate , Male , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/genetics , Piperazines/administration & dosage , Piperazines/adverse effects , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Proto-Oncogene Proteins c-kit/genetics , Pyrimidines/administration & dosage , Pyrimidines/adverse effects , Receptor, Platelet-Derived Growth Factor alpha/genetics
6.
J Pediatr Hematol Oncol ; 28(11): 720-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17114958

ABSTRACT

Tumor vasculature is a reasonable target for cancer therapy and lower more frequent doses of traditional chemotherapeutics [low-dose metronomic (LDM) chemotherapy] has been shown to have antiangiogenic efficacy. This study evaluated the safety and pharmacokinetics of celecoxib and LDM vinblastine or cyclophosphamide in children with recurrent, refractory solid tumors. We also investigated whether a subset of circulating plasma proteins are surrogate markers of angiogenic activity. Thirty-three children were enrolled in this pilot study and received celecoxib (250 mg/m(2) PO b.i.d.) and either vinblastine (1 mg/m(2) IV 3 x /wk) or cyclophosphamide (30 mg/m(2) PO daily) continually. Celecoxib alone and with LDM chemotherapy was well tolerated and plasma concentrations were consistent with those shown to have antiangiogenic activity. Four patients (13%) had durable stable disease (28 to 78 wk) although no complete or partial responses were observed. The surrogate markers measured (vascular endothelial growth factor, basic fibroblast growth factor, soluble vascular cell adhesion molecule, soluble intercellular cell adhesion molecule, endostatin, and thrombospondin-1) were highly variable and no statistically significant relationship between them and disease progression or maintenance of stable disease was observed. We concluded that this regimen is well tolerated hence supporting the use of this form of therapy in pediatric patients. However, future studies should include more homogenous patient populations and focus on validating surrogate markers to monitor treatment activity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/administration & dosage , Neoplasms/drug therapy , Pyrazoles/administration & dosage , Sulfonamides/administration & dosage , Vinblastine/administration & dosage , Adolescent , Angiogenesis Inhibitors , Biomarkers/analysis , Celecoxib , Child , Child, Preschool , Drug Administration Schedule , Female , Humans , Male , Neoplasm Recurrence, Local , Neoplasms/metabolism , Pilot Projects , Pyrazoles/adverse effects , Sulfonamides/adverse effects
7.
J Pediatr Oncol Nurs ; 23(5): 276-85, 2006.
Article in English | MEDLINE | ID: mdl-16902083

ABSTRACT

The aim of this descriptive exploratory study was to determine the perspectives of parents and children with cancer on a home chemotherapy program. Qualitative analyses were used to organize data from 24 parents and 14 children into emerging themes. Themes included (1) financial and time costs, (2) disruption to daily routines, (3) psychological and physical effects, (4) recommendations and caveats, and (5) preference for home chemotherapy. When home chemotherapy was compared with hospital clinic-based chemotherapy, parents reported fewer financial and time costs and less disruption to their work and family schedules, and children reported more time to play/study, improved school attendance, and engagement in normal activities. Although some parents felt more secure with hospital chemotherapy, most found it more exhausting and stressful. At home, children selected places for their treatment and some experienced fewer side effects. Although some coordination/communication problems existed, the majority of parents and children preferred home chemo-therapy. Home chemotherapy treatment is a viable, acceptable, and positive health care delivery alternative from the perspective of parents and children with cancer.


Subject(s)
Attitude to Health , Home Infusion Therapy/psychology , Neoplasms , Parents/psychology , Activities of Daily Living , Adaptation, Psychological , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Child , Choice Behavior , Female , Home Infusion Therapy/adverse effects , Home Infusion Therapy/nursing , Humans , Male , Middle Aged , Neoplasms/drug therapy , Neoplasms/psychology , Nursing Methodology Research , Ontario , Qualitative Research , Quality of Life/psychology , Randomized Controlled Trials as Topic , Stress, Psychological/etiology , Stress, Psychological/psychology , Surveys and Questionnaires , Time Factors
8.
Pediatr Blood Cancer ; 47(3): 285-92, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16200556

ABSTRACT

BACKGROUND: The study objective was to compare a hospital-based and a home-based chemotherapy program for children with acute lymphoblastic leukemia (ALL) in relation to Quality of Life (QOL), safety, caregiver burden, and costs. PROCEDURE: A randomized cross-over trial (RCT) design with repeated measures was conducted with 23 children with ALL who attended the oncology outpatient clinic of a metropolitan university affiliated tertiary level pediatric hospital and who also received home visits from a community health services care provider in central Canada. RESULTS: During the home-treatment phase, children were more capable of maintaining their usual routines than when receiving hospital chemotherapy (Wilcoxon statistic = 80, P = 0.023), but they appeared to experience greater emotional distress (Wilcoxon sign rank statistic S = 66, P = 0.043) according to parental report. Treatment location had no effect on caregiver burden and adverse effects. No significant differences between groups existed with respect to societal costs of care. As the child's age increased, QOL improved relative to younger children (t(20) = -2.37, P = 0.02), the time burden related to child care tasks was reduced (t(21) = -3.56, P = 0.002), caregiver effort/difficulty in physical and behavioral support decreased (t(21) = -2.09, P = 0.049) and the odds of experiencing one or more adverse events decreased (OR = 0.79, CI = (0.63-1.00), chi(1) (2) = 4.01, P = 0.045). CONCLUSIONS: With few differences noted between groups, these results indicate preliminary support for administrating some or all of a child's chemotherapy at home. Home chemotherapy was associated with specific improvements and decrements in parent reported QOL. No effects were seen on burden of care, adverse events, or cost. Overall, young age adversely affected QOL, burden of care, and adverse events. These data provide important information to families and caregivers as they consider home or hospital-based therapy in childhood ALL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Home Care Services, Hospital-Based , Oncology Service, Hospital , Outcome and Process Assessment, Health Care , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Age Factors , Cost of Illness , Cross-Over Studies , Family Health , Health Care Costs , Home Care Services, Hospital-Based/statistics & numerical data , Hospitals, Pediatric , Humans , Oncology Service, Hospital/statistics & numerical data , Ontario , Precursor Cell Lymphoblastic Leukemia-Lymphoma/psychology , Quality of Life , Safety , Sickness Impact Profile , Surveys and Questionnaires
9.
Eur J Oncol Nurs ; 10(3): 198-206, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16384746

ABSTRACT

The ultimate aim of our research program is to provide strategies that facilitate parental decision-making for parents of children with cancer receiving end-of-life care. As a first step to develop this program, we needed insight into parents' reactions and opinions about the research methods planned for a larger study. In particular, we needed their opinions about the general experience of making the decision between palliative cytotoxic chemotherapy and supportive care alone and the factors that parents regard as important when making this decision. In addition, we wished to know whether the methodology proposed for the future study was easy to understand and whether it might cause unnecessary emotional trauma. Finally, we asked their opinions regarding the appropriate target sample of parents to include in the future study. Qualitative data about these issues were collected using focus group methodology involving seven participants. The comments made during the focus group discussions were content-analyzed for common themes. The results from the focus group discussion led to particular modifications in the proposed design and interview strategies planned for the future larger study. We found it was extremely beneficial to include a focus group pre-phase in a study that will interview parents in a high sensitivity area.


Subject(s)
Attitude to Health , Decision Making , Focus Groups/methods , Neoplasms/therapy , Parents/psychology , Patient Selection , Terminal Care/psychology , Adaptation, Psychological , Child , Focus Groups/statistics & numerical data , Helping Behavior , Humans , Morale , Needs Assessment/organization & administration , Neoplasms/psychology , Nurse's Role/psychology , Nursing Methodology Research , Oncology Nursing , Patient-Centered Care , Pediatric Nursing , Professional-Family Relations , Program Development , Qualitative Research , Quality of Life/psychology , Social Support , Surveys and Questionnaires , Terminal Care/methods
11.
Palliat Support Care ; 3(3): 191-6, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16594458

ABSTRACT

OBJECTIVES: To investigate health-related quality of life (HRQOL) in children eligible for Phase 1 trials and the reasons why families consider participating in these trials. METHODS: Individual, semistructured interviews were conducted with parents (seven mothers, two fathers) and three children, after a child was invited to participate in a clinical trial. Information regarding disease and treatment progression, daily life, and decision making about experimental treatments was elicited. Interviews were recorded, transcribed, and coded for themes. RESULTS: HRQOL themes were grouped into four main domains: physical, psychological, social, and spiritual. Minimal physical restrictions, maintaining normalcy and control, information sharing, and having hope for life seemed to be critical HRQOL components. Hope for a cure and prolonging the child's life were the main reasons for enrolling in Phase 1 trials. CONCLUSIONS: Normalcy and control are key end-of-life HRQOL components, and hope for life is a main reason for participating in Phase 1 trials.


Subject(s)
Clinical Trials, Phase I as Topic , Neoplasms/therapy , Palliative Care , Patient Selection , Quality of Life , Adolescent , Canada , Child , Decision Making , Female , Humans , Male , Neoplasms/psychology
12.
Health Soc Care Community ; 12(2): 142-9, 2004 Mar.
Article in English | MEDLINE | ID: mdl-19777723

ABSTRACT

The goal of this study was to determine the perspectives of healthcare professionals (HPs) from community and hospital settings involved in a paediatric home chemotherapy programme. Using a prospective descriptive study design, HPs including paediatricians, community nurses, hospital clinic nurses, administrators and pharmacists were interviewed using a moderately structured open-ended approach. Through inductive content analysis, data were categorised under three themes reflecting HPs' perspectives on the programme: (1) perceived family benefits, (2) human resources and service delivery considerations and (3) impact on the role of the HP. All HPs reported that home chemotherapy helped reduce both disruption to family life and psychological stress. Community-based HPs reported increased job satisfaction, increased workload and increased frustration related to scheduling challenges. Hospital-based HPs reported decreased patient interaction and discrepancies in workload changes. Both groups emphasised the need for consistency in care and for specific chemotherapy training. Service delivery issues included the need for more clarity in the programme process, improved eligibility criteria, a focus on community laboratory coordination and development of centralised communications.


Subject(s)
Attitude of Health Personnel , Community Health Services/organization & administration , Health Personnel/psychology , Home Care Services, Hospital-Based , Stress, Psychological , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Child , Child, Preschool , Data Collection , Female , Home Care Services, Hospital-Based/organization & administration , Humans , Job Satisfaction , Male , Middle Aged , Neoplasms/drug therapy , Neoplasms/nursing , Ontario , Prospective Studies , Qualitative Research , Randomized Controlled Trials as Topic , Surveys and Questionnaires , Workforce , Workload , Young Adult
13.
Clin Pharmacol Ther ; 72(5): 490-7, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12426512

ABSTRACT

BACKGROUND AND OBJECTIVE: Celecoxib is a member of a novel group of agents that selectively inhibit cyclooxygenase 2 (COX-2). COX-2 inhibitors have emerged as an important class of drugs because of the lower incidence of side effects when compared with traditional nonsteroidal anti-inflammatory drugs, which inhibit both cyclooxygenase 1 and COX-2. Because children often differ from adults with respect to drug disposition, the objective of this study was to determine the single-dose and steady-state pharmacokinetics of celecoxib in pediatric patients. METHODS: Celecoxib plasma concentrations were determined at intervals over 12 hours after a 250-mg/m(2) dose and again 1 week later after twice-daily dosing (steady state). RESULTS: Peak plasma concentrations (1234 +/- 528 microg/L) were achieved 3 hours after drug administration. The area under the celecoxib plasma concentration-time curve was 7709 +/- 3176 microg/L x h, the elimination half-life (t(1/2)) was 3.7 +/- 1.1 hours, the apparent volume of distribution was 7.9 +/- 7.8 L/kg, and the lower oral clearance of the drug was 1.4 +/- 1.0 L x h(-1) x kg(-1). Statistical analysis revealed a significantly lower [corrected] apparent oral clearance and longer t(1/2) (P <.05) at steady state compared with pharmacokinetics after a single dose. In addition, when the results were compared in children and adults, the drug was cleared approximately twice as fast in children and had a t(1/2) that was approximately half as long. CONCLUSIONS: This is the first report of celecoxib pharmacokinetics in children, and the results indicate that there are significant differences between children and adults with respect to celecoxib disposition; hence these data may have implications when dosing schedules are planned for this population.


Subject(s)
Cyclooxygenase Inhibitors/pharmacokinetics , Sulfonamides/pharmacokinetics , Adolescent , Age Factors , Celecoxib , Child , Female , Humans , Male , Pyrazoles , Sulfonamides/administration & dosage , Sulfonamides/adverse effects
14.
Cancer ; 95(6): 1294-301, 2002 Sep 15.
Article in English | MEDLINE | ID: mdl-12216098

ABSTRACT

BACKGROUND: Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. METHODS: Patients younger than 21 with recurrent/resistant brain tumors were enrolled in a conventional Phase I study. Fotemustine was administered intravenously every 3 weeks at increasing dose levels starting at 100 mg/m(2). Toxicity and response data were monitored closely. RESULTS: Fifteen evaluable patients entered the study and received a total of 45 courses of fotemustine (dose range, 100-175 mg/m(2)). Myelosuppression was observed, with the dose-limiting toxicity being Grade 4 neutropenia and thrombocytopenia. Toxicity was delayed and cumulative. The maximum tolerated dose was 150 mg/m(2) every 3 weeks. There were three documented radiologic responses (20% of patients) comprising one partial response and two minor responses in patients with a sarcoma, medulloblastoma, and ependymoma, respectively. CONCLUSIONS: Fotemustine administered at a dose of 150 mg/m(2) every 3 weeks is well tolerated in children and has antitumor activity in several brain tumors. This is the first dedicated Phase I study of a single agent nitrosourea in a pediatric population. More comparative studies should be undertaken to define the optimum nitrosourea analog for use in children with brain tumors.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Nitrosourea Compounds/therapeutic use , Organophosphorus Compounds/therapeutic use , Adolescent , Anemia/chemically induced , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Child , Child, Preschool , Ependymoma/drug therapy , Female , Humans , Infant , Injections, Intravenous , Male , Medulloblastoma/drug therapy , Neutropenia/chemically induced , Nitrosourea Compounds/administration & dosage , Nitrosourea Compounds/adverse effects , Organophosphorus Compounds/administration & dosage , Organophosphorus Compounds/adverse effects , Sarcoma/drug therapy , Thrombocytopenia/chemically induced , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...